Clinical Report: Epidemiology and Management of Difficult-to-Treat Inflammatory Bowel Disease

Overview

In a retrospective study of 1736 IBD patients treated with advanced therapies, 24.8% met criteria for difficult-to-treat IBD (DTT-IBD). Key risk factors included extensive disease in ulcerative colitis and complicated phenotypes in Crohn’s disease, with drug persistence decreasing progressively with each subsequent treatment line.

Background

Inflammatory bowel diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic conditions with variable response to treatment. Despite an expanding arsenal of biologics and small molecules, a significant subset of patients exhibit refractory disease, termed difficult-to-treat IBD (DTT-IBD). The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) recently standardized DTT-IBD criteria to facilitate research and clinical management. Understanding the prevalence, risk factors, and outcomes of DTT-IBD is critical for optimizing therapeutic strategies.

Data Highlights

Key Findings

• Approximately one-quarter (24.8%) of IBD patients treated with biologics or advanced small molecules met criteria for DTT-IBD.
• In UC, left-sided and extended colitis significantly increased risk of DTT compared to proctitis (OR 6.55 and 10.12, respectively).
• In CD, multiple disease locations, stricturing and penetrating behaviors, and perianal disease were major risk factors for DTT (ORs ranging from 2.24 to 3.04).
• Delay in initiating advanced treatment was associated with increased risk of DTT in CD (OR 1.74) but was protective in UC (OR 0.65).
• Symptomatic, biochemical, and especially endoscopic remission rates were significantly lower in DTT-IBD patients compared to non-DTT-IBD.
• Drug persistence decreased progressively with each subsequent line of therapy in both CD and UC, with similar persistence across different advanced drugs used in DTT-IBD.

Clinical Implications

Clinicians should recognize that certain phenotypes, such as extensive UC and complicated CD, are at higher risk for difficult-to-treat disease and may require earlier or more aggressive intervention. Monitoring and minimizing delays in initiating advanced therapies, particularly in CD, could improve outcomes. Awareness of decreasing drug persistence with successive therapies underscores the need for personalized treatment strategies and consideration of alternative approaches in refractory cases.

Conclusion

DTT-IBD affects a significant subset of patients with moderate-to-severe IBD, characterized by distinct clinical risk factors and poorer treatment outcomes. Early identification and tailored management strategies are essential to improve disease control and patient prognosis.

References

1. International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Consensus 2023 -- Definition and Criteria of Difficult-to-Treat IBD
2. San Raffaele and Humanitas Research Hospitals, Milan, Italy 2024 -- Epidemiology and Outcomes of DTT-IBD